China Transmucosal Drug Delivery Systems Market to 2027 – Regional Analysis and Forecasts – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “China Transmucosal Drug Delivery Systems Market to 2027 – Regional Analysis and Forecasts by Route of Administration; Age Group; End User” report has been added to ResearchAndMarkets.com’s offering.

The China transmucosal drug delivery systems market is expected to reach US$ 24,518.6 Mn in 2027 from US$ 9,520.3 Mn in 2018. The market is estimated to grow with a CAGR of 11.2% from 2019-2027.

Rising prevalence of various chronic diseases such as respiratory, gastrointestinal, and autoimmune diseases are expected to surge the market growth. Moreover, the advantages offered by transmucosal route of administration increasing its adaptability is also responsible for boosting the market growth over the years. However, high cost of production of drug delivery devices under stringent regulatory observation is likely to have a negative impact on the growth of the market in the coming years.

China is facing a grim reality in case of chronic diseases in the country. According to the World Health Organization (WHO), 86.6% of deaths in China are accounted due to chronic diseases. The incidence of chronic disease has risen rapidly in recent years. According to Chinese Center for Disease Control and Prevention (CCDC), China has reached a health tipping point in 2016, where the chronic diseases were recording among more than 300 million patients in the country. Unhealthy and sedentary lifestyles are known to be the common factors laying behind the rise of these diseases in the country.

According to the Institute of Health Matrix and Evolution (IHME), Stroke, ischemic heart disease, lung disease, chronic obstructive pulmonary disease (COPD) and liver cancer are the top five chronic conditions found among the patients suffering with chronic diseases, more than half of which are under the age of 65 years. National diabetes rates increased by more than 50%, from 4,206 prevalent cases per 100,000 in 2000 to 6,336 prevalent cases in 2017. An estimated 6.3% of the population were suffering from diabetes in 2017.

Reasons to Buy

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the transmucosal delivery systems market.
• Highlights key business priorities in order to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in the transmucosal delivery systems market, thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
  

Key Topics Covered:

1. Introduction

2. China Transmucosal Drug Delivery Systems Market – Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. China Transmucosal Drug Delivery Systems Market – Market Landscape

4.1 Overview

4.2 PEST Analysis

4.2.1 China PEST Analysis

4.3 Expert Opinions

4.4 Epidemiology Data

4.5 Regulatory Scenario for Methotryxate in China

4.6 Pricing Analysis

5. Transmucosal Drug Delivery Systems Market – Key Industry Dynamics

5.1 Key Market Drivers

5.1.1 Rising Prevalence of Chronic Diseases

5.1.2 Advantages of Transmucosal Drug Delivery

5.2 Key Market Restraint

5.2.1 High Cost Involved in the Development of Drug Delivery Devices

5.3 Key Market Opportunity

5.3.1 Increasing Preference Towards Self-Administration and Home Care

5.4 Future Trend

5.4.1 Research and Development in Transmucosal Drug Delivery

5.5 Impact Analysis

6. China Transmucosal Drug Delivery Systems Market – China Market Analysis

6.1 Overview

6.2 China Transmucosal Drug Delivery Systems Market – Revenue Forecasts and Analysis – 2018- 2027

7. China Transmucosal Drug Delivery Systems Market Analysis- by Route of Administration

7.1 Overview

7.2 China Transmucosal Drug Delivery Systems Market, By Route of Administration 2018 & 2027 (%)

7.3 Oral Market

7.4 Vaginal Market

7.5 Nasal Market

7.6 Urethral/Rectal Market

8. China Transmucosal Drug Delivery Systems Market Analysis- by Age Group

8.1 Overview

8.2 China Transmucosal Drug Delivery Systems Market, By Age Group 2018 & 2027 (%)

8.3 Adults Market

8.4 Pediatrics Market

9. China Transmucosal Drug Delivery Systems Market Analysis- by End User

9.1 Overview

9.2 China Transmucosal Drug Delivery Systems Market, By End User 2018 & 2027 (%)

9.3 Hospitals Market

9.4 Overview

9.5 China Hospitals Market Revenue and Forecasts to 2027 (US$ Mn)

9.6 Clinics Market

9.7 Others Market

10. Transmucosal Drug Delivery Systems Market – Industry Landscape

10.1 Overview

10.2 Growth Strategies done by the companies in the Market, (%)

10.3 Organic Developments

10.3.1 Overview

10.4 Inorganic developments

10.4.1 Overview

11. Transmucosal Drug Delivery Systems Market-Key Company Profiles

Companies Mentioned

• 3M
• Acrux Limited
• GW Pharmaceuticals plc
• INTELGENX CORP
• Mylan N.V.
• Novartis AG
• Reckitt Benckiser Group plc.
• Teva Pharmaceutical Industries Ltd
• UCB S.A.
• West Pharmaceutical Development, LLC
  

For more information about this report visit https://www.researchandmarkets.com/r/gposxb

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900